PL 02.02 Patient-Reported Outcomes with Durvalumab after Chemoradiation in Locally Advanced, Unresectable NSCLC: Data from PACIFIC

Hui, Rina; Özgüroǧlu, Mustafa; Daniel, Davey B.; Baz, David Vicente; Murakami, Shuji; Yokoi, Takashi; Chiappori, Alberto; Lee, K.H.; Wit, Maike de; Cho, B. Chul; Gray, Jhanelle E.; Rydén, Anna; Viviers, Louis; Poole, Lynne; Dennis, Phillip A.; Antonia, Scott

doi:10.1016/j.jtho.2017.09.096

Search citation statements

Order By: Relevance

Paper Sections

Select...

Formatted For Apjco1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

2023

Publication Types

Select...

Article2

Book2

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…59 Toxicities were manageable and patient reported outcome data also showed that quality of life was not compromised by adding 12 months of durvalumab after standard concurrent chemoradiation. 60 This article is protected by copyright. All rights reserved.10…”

Section: Formatted For Apjcomentioning

confidence: 99%

Patterns of care for stage III non–small cell lung cancer in Australia

Parente

Chan

Hughes

et al. 2019

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

providing medical writing support by preparing the manuscript outline, developing the first draft and collating and incorporating author comments to the final manuscript. Medical writing support was funded by AstraZeneca, Sydney, Australia in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).Insight and stimulus for this manuscript was identified during metropolitan roundtable meetings led by AstraZeneca in Australia. Australian medical oncologists, radiation oncologists, cardiothoracic surgeons, respiratory physicians and cancer care nurses participated in these meetings including the authors of this manuscript.

show abstract

Section: Formatted For Apjcomentioning

confidence: 99%